Biotech: Stubbornly Unconsolidated
A few 1994-95 biotech acquisitions seemed to hint at the always tantalizing possibility that Big Pharma would pay handsomely for biotech's innovation by buying the companies.But buying drug related biotech stocks in the hopes of high-value acquisitions looks a lot like Lotto odds.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.